[1] Siegl, Rebecca L, Miller R, et al. Cancer statistics, 2019[J]. CA: A Cancer Journal for Clinicians, 2019, 69(1):7-34. [2] Chen J, Shao R, Li L, et al.Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5- FU and PI3K、mTOR dual inhibitor BEZ- 235 through apoptotic pathways[J]. Int JNanomed, 2014, 16(9): 3403-3441. [3] Li L, Liu D, Qiu ZX, et al.The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(2): 1-13. [4] Yu G, Wang J, Chen Y, et al.Overexpression of phosphorylated mammalian target of rapamycin predicts lymph nodemetastasis and prognosis of chinese patients with gastric cancer[J]. Clin Cancer Res, 2009, 15(5): 1821-1829. [5] Xiao L, Wang YC, Li WS, et al.The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray[J]. J Exp Clin Cancer Res, 2009, 28: 152-160. [6] Azim HA, Kassem L, Treilleux I, et al.Analysis of PI3K、mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer[J]. Transl Oncol, 2016, 9(2): 114-123. [7] Li S, Kong Y, Si L, et al.Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma[J]. BMC Cancer, 2014, 32(15): 376-389. [8] Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. European Journal of Epidemiology, 2010, 25(9): 603-605. [9] 项洪刚,王强,胡志前,等. 人结直肠癌组织中EGFR、Grb2、p-mTOR、VEGF的表达及意义[J]. 第二军医大学学报,2009,30(7):775-779. [10] 张毅,张甘露,王俊红,等. 直肠癌组织Akt-mTOR蛋白表达与临床病理因素相关性分析[J]. 中华肿瘤防治杂志,2013,20(4):296-300. [11] 汪砥,陈健,陈辉,等. 瘦素与p-mTOR在大肠癌中的表达及临床意义[J]. 中南大学学报(医学版),2012,37(3):233-237. [12] 孙琦. Akt、TGF-β1、mTOR在结直肠癌中的表达及意义[J]. 现代中西医结合杂志,2015,24(21):2351-2352,2374. [13] 王茜,时延龙,毕经旺. p-mTOR与HIF-1α在结直肠癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志,2015,22(6):779-784. [14] 张利,吴慧丽,李琨琨,等. mTOR及PTEN、PHLPP、VEGF、p53蛋白在结肠癌中的表达及意义[J].中国临床研究,2015,28(12):1567-1569. [15] 林萍,邓涛,叶彦,等. 人结直肠癌组织中mTOR、HIF-1α、PKM2的表达及临床意义[J]. 疑难病杂志,2015,14(4):380-383,441. [16] 赵溢斐,周逢强,徐宏,等. 结肠癌中p-mTOR、p-p70S6K的表达与临床病理意义[J]. 中国医学创新,2018,15(2):46-49. [17] 孙红兰,刘慧峰,姜国丹. p-MTOR在结肠癌中的表达及与患者病理学特征的关系[J]. 癌症进展,2018,16(1):70-72,87. [18] 陈在昌,胡永伟,朱荣,等. Survivin与p-mTOR在人肠癌组织中的表达及其相关性分析[J]. 现代肿瘤医学,2017,25(20):3271-3275. [19] 吴淑华,胡金龙,何双,等. 大肠癌中Beclin1、LC3和mTOR的表达及意义[J]. 临床与实验病理学杂志,2014,30(12):1333-1338. [20] Kwasnicki A, Jeevan D, Braun A, et al.Involvement of mTORSignaling Pathways in Regulating Growth and Dissemination of Metastatic Brain Tumors via EMT[J]. Anticancer Res, 2015, 35(2): 689-696. [21] Michael W.Ronellenfitsch; Anna-Luisa Luger and Joachim P. Steinbach.EGFR and mTOR as therapeutic targets in glioblastoma[J]. Oncotarget, 2019, 10(46): 4721-4723. [22] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease[J]. Cell, 2017, 168(6): 960-976. [23] 俞燕丽,傅睿. 连翘提取物通过PI3K-AKT-mTOR信号通路逆转结肠癌氟尿嘧啶耐药细胞株的研究[J].新中医,2019,51(5):27-30. [24] 肖忠盛,龙泓,丁成明,等. 白藜芦醇通过调控mTOR 信号通路抑制结直肠癌细胞的增殖和糖酵解作用[J]. 实用医学杂志,2019,35(14):2210-2214. [25] Guan YD, Jiang SL, Yu P, et al.Suppression of eEF-2K-mediated autophagy enhances the cytotoxicity of raddeanin A against human breast cancer cells in vitro[J]. Acta Pharmacologica Sinica, 2018, 39(4): 642-648. |